Peptides for Belly Fat: What the Research Actually Shows

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.

---

Peptides for Belly Fat: What the Research Actually Shows

Not all body fat is equal. The fat sitting around your organs, called visceral adipose tissue (VAT), is the kind that drives metabolic disease. It raises your risk for type 2 diabetes, cardiovascular disease, and fatty liver disease in ways that subcutaneous fat (the kind you can pinch) does not.

This is why "belly fat" is more than a cosmetic concern. It is a metabolic one.

Several peptides are being studied for their effects on visceral fat specifically. Some have FDA approval for related conditions. Others are still in early research. Here is what the published data actually shows for each one, without the hype.

---

Key Takeaways

• Visceral fat is metabolically dangerous fat that wraps around abdominal organs. It is a stronger predictor of metabolic disease than total body weight.
• Tesamorelin is the only peptide FDA-approved for a condition involving visceral fat (HIV-associated lipodystrophy). It reduced visceral fat by roughly 15-18% in clinical trials.
• AOD-9604 (HGH fragment 176-191) showed fat metabolism effects in animal studies, but published human trial data is limited.
• Retatrutide is an investigational triple-agonist. Phase 2 data showed fat mass reductions of 15.2% to 26.1%, with a glucagon receptor component that directly drives hepatic lipid oxidation.
• CJC-1295 stimulates growth hormone release, which plays a role in fat metabolism. But it is not FDA-approved for any indication.
• None of these peptides are approved for general belly fat reduction. Speak with a physician before considering any peptide protocol.

---

Why Visceral Fat Matters More Than the Scale

Your bathroom scale cannot tell the difference between someone carrying 30 pounds of subcutaneous fat and someone carrying 30 pounds of visceral fat. But your metabolic health can.

Visceral adipose tissue (VAT) surrounds the liver, intestines, and other abdominal organs. Unlike subcutaneous fat, visceral fat is metabolically active. It releases free fatty acids directly into the portal circulation, which feeds the liver. This contributes to insulin resistance, elevated triglycerides, systemic inflammation, and non-alcoholic fatty liver disease.

A person with a "normal" BMI can still carry dangerous levels of visceral fat. This is sometimes called TOFI: thin outside, fat inside.

The peptides discussed below target different pathways involved in fat metabolism. Some work through growth hormone signaling. Others work through incretin hormones or glucagon receptor activation. The mechanisms matter because they determine where and how fat is mobilized.

---

Tesamorelin: The Only FDA-Approved Option (for a Specific Use)

Tesamorelin (brand name Egrifta) holds a position no other peptide on this list can claim. It is FDA-approved.

The approval is narrow: tesamorelin is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a condition where fat redistributes abnormally, often accumulating in the abdomen while wasting from the extremities and face. It is a known side effect of certain antiretroviral medications.

What the Trial Data Shows

The Phase 3 trial published by Falutz et al. in JAMA (2007) demonstrated that tesamorelin produced a statistically significant reduction in visceral adipose tissue compared to placebo in HIV patients with lipodystrophy.

Key findings from the clinical program:

• VAT reduction of approximately 15-18% over 26 weeks on the approved dose
• The effect was specific to visceral fat. Subcutaneous fat and lean mass were largely preserved.
• Benefits reversed when the drug was discontinued, suggesting ongoing treatment is needed for maintained results

How Tesamorelin Works

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and release growth hormone (GH). GH, in turn, promotes lipolysis (fat breakdown), particularly in visceral fat depots.

The specificity for visceral fat is notable. Growth hormone receptors are more densely expressed in visceral adipose tissue than in subcutaneous fat. This receptor distribution may explain why GH-pathway interventions tend to preferentially affect abdominal fat stores.

The Limitations

Tesamorelin is not approved for general obesity or belly fat reduction in the broader population. Off-label use exists, but the published evidence base is specific to HIV lipodystrophy. Potential side effects include joint pain, peripheral edema, and glucose intolerance. IGF-1 levels should be monitored during use.

For anyone considering tesamorelin, this is a prescription medication that requires physician oversight.

---

AOD-9604: The Growth Hormone Fragment

AOD-9604 is a modified fragment of human growth hormone. Specifically, it corresponds to amino acids 176-191 of the HGH molecule, with an added tyrosine residue. The idea behind it: isolate the fat-burning portion of growth hormone while leaving behind the growth-promoting (and potentially problematic) effects.

What the Research Shows

The foundational research on AOD-9604 comes from Heffernan et al., published in Obesity Research (2001). This study examined the lipolytic (fat-breaking) activity of HGH fragment 176-191 in animal models.

The findings showed that the fragment stimulated lipolysis in a manner similar to full-length growth hormone, without the diabetogenic effects that full HGH can produce. In obese mouse models, AOD-9604 reduced body fat without affecting food intake or inducing the insulin resistance associated with exogenous growth hormone.

Here is the critical caveat: the published human clinical data for AOD-9604 is thin. A Phase 2B clinical trial conducted in the early 2000s in obese adults did not produce the statistically significant weight loss results needed to advance the program. The drug did not progress to Phase 3 for obesity.

Current Status

AOD-9604 is not FDA-approved for any indication. It remains a research compound. It received GRAS (Generally Recognized as Safe) status from the FDA when used as a food ingredient at very low doses, but that is not the same as drug approval for fat loss.

The peptide research community continues to discuss AOD-9604, and anecdotal reports are widely shared online. But as of this writing, the peer-reviewed human evidence supporting its use for belly fat reduction is limited.

---

Retatrutide: The Investigational Triple-Agonist

Retatrutide is the most talked-about investigational obesity compound right now, and its body composition data is part of the reason.

Unlike single-target peptides, retatrutide activates three receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. Each pathway contributes differently to fat metabolism.

Phase 2 Body Composition Data

Published data from the Phase 2 trial program tells a compelling story about fat loss specifically.

Fat mass reductions ranged from 15.2% to 26.1% across dose groups, as reported in body composition analyses (PMID 40609566). Total body weight loss reached up to 24.2% at 48 weeks on the highest dose in the main Phase 2 trial (PMID 37366315).

But the number that matters most for visceral fat is the liver data. A substudy showed 86% reduction in liver fat content at 24 weeks on the 12 mg dose (PMID 38858523). Liver fat accumulation is driven directly by visceral adiposity through free fatty acid release into the portal vein. Reducing liver fat at this magnitude suggests substantial visceral fat mobilization.

Why the Glucagon Receptor Matters for Belly Fat

This is where retatrutide differs from GLP-1-only drugs like semaglutide.

The glucagon receptor component directly activates hepatic lipid oxidation. In plain language: it tells liver cells to burn stored fat rather than accumulate it. This is a direct signal, not a passive result of weight loss.

First-generation GLP-1 drugs do reduce visceral fat, but primarily as a secondary effect of overall calorie reduction and weight loss. Retatrutide adds a targeted hepatic fat-burning pathway on top of that. This dual mechanism (systemic weight loss plus direct liver fat oxidation) may explain the extraordinary liver fat reduction numbers in the Phase 2 data.

The Lean Mass Question

One concern with any rapid weight loss intervention is lean mass preservation. The semaglutide STEP 1 trial (PMID 33567185) showed that approximately 40% of total weight lost on semaglutide was lean mass rather than fat mass. That ratio has become a focal point for the entire GLP-1 drug class.

Retatrutide's body composition data suggests a potentially more favorable fat-to-lean mass loss ratio compared to GLP-1-only compounds, though this needs confirmation in larger Phase 3 trials. The GIP receptor component may play a protective role for lean tissue, though the mechanism is still being studied.

Current Status

Retatrutide is in Phase 3 trials (the TRIUMPH program) run by Eli Lilly. It is not FDA-approved and is not available outside of clinical trials as of March 2026. For more on retatrutide, see our complete guide and our coverage of retatrutide and liver health.

---

CJC-1295: The Growth Hormone Secretagogue

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), similar in concept to tesamorelin but with a key difference: it is not FDA-approved for any indication.

How It Works

CJC-1295 binds to the GHRH receptor on the pituitary gland and stimulates the release of endogenous growth hormone. A modified version (CJC-1295 with DAC, or drug affinity complex) extends the half-life, allowing for less frequent dosing.

The pharmacology was characterized by Teichman et al. (PMID 16352683), who documented dose-dependent increases in GH and IGF-1 levels following CJC-1295 administration.

The connection to belly fat is the same GH pathway that makes tesamorelin effective: elevated growth hormone promotes lipolysis, with preferential activity in visceral fat depots due to receptor density.

The Evidence Gap

CJC-1295 never completed the clinical trial pathway required for FDA approval. The published data supports its pharmacological activity (it does raise GH levels), but there are no large controlled trials demonstrating statistically significant visceral fat reduction in humans.

The peptide research community frequently pairs CJC-1295 with ipamorelin (a growth hormone-releasing peptide) as a combination protocol. Published evidence for this specific combination in human fat loss studies is not available. The rationale is based on pharmacological theory and anecdotal reporting, not controlled trial data.

---

How These Peptides Compare

Peptide	Mechanism	FDA Status	Visceral Fat Evidence
Tesamorelin (Egrifta)	GHRH analog, stimulates GH release	FDA-approved (HIV lipodystrophy)	Strong: Phase 3 RCTs, 15-18% VAT reduction
AOD-9604	HGH fragment 176-191, lipolysis	Not approved	Weak: animal data positive, human trials inconclusive
Retatrutide	GLP-1/GIP/glucagon triple agonist	Investigational (Phase 3)	Promising: Phase 2 fat mass reduction 15-26%, 86% liver fat reduction
CJC-1295	GHRH analog, stimulates GH release	Not approved	Limited: pharmacology confirmed, no fat loss RCTs

The honest summary: tesamorelin has the strongest established evidence for visceral fat reduction, but only in HIV lipodystrophy. Retatrutide has the most promising early data for general visceral fat, but it is years away from potential approval. AOD-9604 and CJC-1295 have pharmacological rationale but lack the published clinical trial data to make strong claims.

---

What About GLP-1 Drugs Already on the Market?

Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for weight management. Both reduce visceral fat as part of overall weight loss.

The STEP 1 trial for semaglutide (PMID 33567185) showed 14.9% body weight reduction at 68 weeks. Body composition substudies in the GLP-1 class have generally shown visceral fat reductions proportional to total weight loss.

These are the most accessible, evidence-backed options available right now for people whose primary goal is reducing abdominal fat. They require a prescription and physician monitoring.

For a broader look at peptide-based fat loss approaches, see our fat loss goals page.

---

The Bottom Line

Visceral belly fat is a metabolic problem, not just a cosmetic one. Several peptides show promise for targeting it through different biological pathways.

Tesamorelin has real clinical data and FDA approval, though limited to HIV lipodystrophy. Retatrutide's Phase 2 numbers are striking, but Phase 3 confirmation is still in progress. AOD-9604 and CJC-1295 have interesting mechanisms but lack the published human trial data to support confident conclusions.

The research is moving fast. New data from retatrutide's TRIUMPH trials will be especially important to watch.

For anyone dealing with excess visceral fat today, the best starting point is a conversation with a physician who can assess your metabolic health, review the available evidence, and help you weigh the options that actually have clinical support behind them.

---

Frequently Asked Questions {#faq}

What are the best peptides for belly fat?

Based on published research, tesamorelin has the strongest clinical evidence for visceral fat reduction, though it is only FDA-approved for HIV-associated lipodystrophy. Retatrutide has shown promising Phase 2 data for total fat mass and liver fat reduction. AOD-9604 and CJC-1295 have pharmacological rationale but limited human trial data. No peptide is FDA-approved specifically for general belly fat reduction.

Does tesamorelin reduce belly fat?

Yes. In Phase 3 clinical trials for HIV lipodystrophy, tesamorelin reduced visceral adipose tissue by approximately 15-18% over 26 weeks. It works by stimulating growth hormone release, which promotes fat breakdown preferentially in visceral fat depots. It is FDA-approved as Egrifta for this specific condition but not for general obesity.

Is AOD-9604 effective for fat loss?

Animal studies published by Heffernan et al. (2001) showed that AOD-9604 stimulated lipolysis without the insulin resistance associated with full growth hormone. However, a Phase 2B human trial in obese adults did not produce statistically significant weight loss results, and the compound did not advance to Phase 3 for obesity. Human evidence remains limited.

How does retatrutide target visceral fat?

Retatrutide activates three receptors: GLP-1, GIP, and the glucagon receptor. The glucagon component is especially relevant for visceral fat because it directly activates hepatic lipid oxidation, telling liver cells to burn stored fat. Phase 2 data showed fat mass reductions of 15.2% to 26.1% and an 86% reduction in liver fat at 24 weeks. Retatrutide is investigational and currently in Phase 3 trials.

Can peptides reduce visceral fat without losing muscle?

This is an active area of research. GLP-1 drugs like semaglutide have shown that roughly 40% of weight lost can be lean mass. Retatrutide's early data suggests a potentially more favorable fat-to-lean ratio, but Phase 3 confirmation is needed. Resistance training and adequate protein intake (1.2-1.6g per kg body weight) are recommended during any weight loss intervention to preserve lean mass.

Are peptides for belly fat safe?

Safety profiles vary by compound. Tesamorelin is FDA-approved with known side effects including joint pain, edema, and glucose changes. Retatrutide's Phase 2 safety data showed GI side effects (nausea, diarrhea) common to GLP-1 drugs. AOD-9604 and CJC-1295 are not FDA-approved, which means less safety data is available. Always work with a physician before starting any peptide protocol.

---

Related Reading

• Peptide Fat Loss Guide: Complete Research Overview
• Tesamorelin: Mechanism, Research, and What to Know
• AOD-9604: The HGH Fragment for Fat Metabolism
• Retatrutide Complete Guide: The Triple-Agonist Explained
• Retatrutide and Liver Health: What the MASH/MASLD Research Shows

---

Medical Disclaimer

This article is produced by the Peptide Nerds editorial team for informational and educational purposes only. We are not physicians, pharmacists, or licensed healthcare providers. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations.

Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy only. It is not approved for general obesity or belly fat reduction. AOD-9604 and CJC-1295 are research compounds and are not FDA-approved for any indication. Retatrutide is an investigational compound currently in Phase 3 clinical trials and is not available outside of those trials.

All treatment decisions should be made with a qualified physician who can evaluate your individual health status. Individual results vary. Always consult a qualified healthcare provider before starting, changing, or stopping any medication, supplement, or health protocol.

---

Sources

1. Falutz J, et al. Effects of tesamorelin on visceral fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2007. Phase 3 trial data for tesamorelin in HIV lipodystrophy.
2. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Obesity Research. 2001 (PMID: 11574842). HGH fragment 176-191 lipolysis mechanism in animal models.
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
4. Retatrutide fat mass and body composition data. PMID 40609566
5. Retatrutide liver fat reduction substudy, Phase 2. PMID 38858523
6. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006. PMID 16352683
7. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185

---